EC Clinical and Medical Case Reports

In the history of vaccination, we have savings of lives of people of different ages from children aged 0 days and the very old people.

Before using the rotavirus vaccine in USA 4 or 5 children had symptomatic rotavirus gastroenteritis (RVGE) [1], 1 in 7 children required a clinic or emergency department visit, 1 in 70 cases was hospitalized, one case in 200,000 would die from this disease within age 5 years old [2]. The cost of this situation was estimated approximately $ 1 billion [3]. The situation in developing countries related to rotavirus gastroenteritis continues to be a major cause of severe childhood morbidity, with approximately half a million deaths per year among children aged < 5 years [4].

Of the estimated 8.795 million deaths in children younger than 5 years worldwide in 2008, infectious diseases caused 68% (5.970 million), with the largest percentages due to pneumonia (18%, 1.575 million, uncertainty range [UR] 1.046 million - 1.874 million), diarrhea (15%, 1.336 million, 0.822 million - 2.004 million), and malaria (8%, 0.732 million, 0.601 million - 0.851 million). 41% (3.575 million) of deaths occurred in neonates, and the most important single causes were preterm birth complications (12%, 1.033 million, UR 0.717 million - 1.216 million), birth asphyxia (9%, 0.814 million, 0.563 million - 0.997 million), sepsis (6%, 0.521 million, 0.356 million - 0.735 million), and pneumonia (4%, 0.386 million, 0.264 million-0.545 million). 49% (4.294 million) of child deaths occurred in five countries: India, Nigeria, the Democratic Republic of the Congo, Pakistan, and China [5].

Keywords: Rotavirus Vaccine; Infection; Intussusception; Safety; Countries; Case

1. Rodriguez WJ., et al. “Longitudinal study of rotavirus infection and gastroenteritis in families served by a pediatric medical practice: clinical and epidemiologic observations”. Pediatric Infectious Disease Journal 2 (1987): 170-176.
2. Glass RI., et al. “The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden”. Journal of Infectious Diseases 1 (1996): S5-S11.
3. Kilgore PE., et al. “Trends of diarrheal disease-associated mortality in U.S. children, 1968 through 1991”. Journal of the American Medical Association14 (1995): 1143-1148.
4. Parashar UD., et al. “Global illness and deaths caused by rotavirus disease in children”. Emerging Infectious Diseases 5 (2003): 565-572.
5. Black RE., et al. “Child Health Epidemiology Reference Group of WHO and UNICEF, Global, regional, and national causes of child mortality in 2008: a systematic analysis”. Lancet9730 (2010): 1969-1987.
6. Butz AM., et al. “Prevalence of rotavirus on high-risk fomites in daycare facilities”. Pediatrics2 (1993): 202-205.
7. https://en.wikipedia.org/wiki/Rotavirus
8. https://en.wikipedia.org/wiki/Rotavirus
9. Lestari BF., et al. “Rotavirus infection in children in Southeast Asia 2008-2018: disease burden, genotype distribution, seasonality, and vaccination”. Journal of Biomedical Science 1 (2020): 66.
10. Cenko F., et al. “Circulation of Enteric Viruses in Tirana, Albania: Situation Ten Years After the First Study”. New Microbiologica2 (2022): 138-141.
11. https://shendetesia.gov.al/vaksine-e-re-ne-shqiperi-manastirliu-vaksina-e-rotavirusit-falas-per-30-mije-femije-ne-vit/
12. https://www.ishp.gov.al/departamenti-i-kontrollit-te-semundjeve-infektive/programi-kombetar-i-vaksinimit/
13. ECDC Scientific Advice Expert opinion on rotavirus vaccination in infancy (2017).
14. Margaret M Cortese and Penina Haber. Rotavirus, MPH (2021).
15. https://www.cdc.gov/vaccinesafety/vaccines/rotavirus-vaccine.html
16. https://www.cdc.gov/vaccines/hcp/vis/vis-statements/rotavirus.html
17. Poelaert D., et al. “A review of recommendations for rotavirus vaccination in Europe: Arguments for change”. Vaccine17 (2018): 2243-2253.
18. Rotavirus vaccine side effects.
19. Tsugawa T., et al. “Rotavirus vaccination in Japan: Efficacy and safety of vaccines, changes in genotype, and surveillance efforts”. Journal of Infection and Chemotherapy7 (2021): 940-948.
20. Rao T S., et al. “Insights from global data for use of rotavirus vaccines in India”. Vaccine 1 (2014): A171-A178.
21. Kirkwood DC and Steele AD. “Rotavirus Vaccines in China Improvement Still Required”. JAMA Network Open4 (2018): e181579.
22. Reddy S., et al. “Safety monitoring of ROTAVAC vaccine and etiological investigation of intussusception in India: study protocol”. BMC Public Health1 (2018): 898.
23. Jehangir S., et al. “Intussusception in southern India: Comparison of retrospective analysis and active surveillance”. Vaccine1 (2014): A99-A103.
24. Felicetti P., et al. “Spontaneous reports of vasculitis as an adverse event following immunization: A descriptive analysis across three international databases”. Vaccine51 (2016): 6634-6640.
25. Henschkea N., et al. “The efficacy and safety of rotavirus vaccines in countries in Africa and Asia with high child mortality”. Vaccine12 (2022): 1707-1711.
26. Velázquez FR., et al. “Efficacy, safety and effectiveness of licensed rotavirus vaccines: a systematic review and meta-analysis for Latin America and the Caribbean”. BMC Pediatrics 17 (2017): 14.
27. Dey A., et al. “Surveillance of Adverse events following immunization in Australia annual report, 2020”. Communicable Diseases Intelligence 46 (2022).
28. Pérez-Vilarab S., et al. “Intussusception following rotavirus vaccination in the Valencia Region, Spain”. Human Vaccines and Immunotherapeutics 7 (2015): 1848-1852.
29. Leino T., et al. “Evaluation of the Intussusception Risk after Pentavalent Rotavirus Vaccination in Finnish Infants”. PLOS ONE3 (2016): e0144812.
30. Trotta F., et al. “Intussusception hospitalizations incidence in the pediatric population in Italy: a nationwide cross-sectional study”. Italian Journal of Pediatrics1 (2016): 89.